Plenary Sessions-24/04/2021

Saturday, April 24th, 2021

11:00 - 13:00

Poster Discussion 


Poster Session 2 - EPIDEMIOLOGY I


15:00 - 16:30

Plenary session 2: Hematological malignancies

Chairs: H. Ten Cate (The Netherlands), F. Rodeghiero (Italy)

PL-10 - Risk-assessment of thrombosis and bleeding in hematological malignancies
B. Brenner (Israel)

PL-11 - Advances in management of coagulopathy in APL
M.A. Sanz (Spain)

PL-12 - Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia
A. Leader (Israel)

PL-13 - Multiple myeloma-associated VTE risk prediction
K. Sanfilippo (USA)

Selected Abstract

OC-06 - The Molecular Mechanisms of Ponatinib-Induced Thrombosis
A.H. Schmaier, A.A. Merkulova, E.R. Chan, E.X. Stavrou, S.C. Mitchell, G.L. Forbes, P. Zeng (USA)

OC-07 - Differences in Thromboprophylaxis Between Hospitalized Patients with Solid or Hematological Malignancies
R. Figueroa, M. Marcos-Jubilar, A. García-Mouriz, J.A. Páramo, R. Lecumberri (Spain)

16:30 - 17:00 

Roundtable: Emerging practical guidelines for the prevention and treatment of CAT

Chairs: M. Cattaneo (Italy), R. Labianca (Italy)

Introduction: Overview of VTE treatment and prevention in cancer according to clinical guidelines
G. Lyman (USA)

Discussant: G. Lyman (USA)I. Elalamy (France), A. Falanga (Italy), D. Farge (France), K. Jordan (Germany), A. Lee (Canada)


17:00 – 18:45

Plenary Session 3: Biomarkers in CAT and cancer progression

Chairs: N. Mackman (USA), A.K. Olsson (Sweden)

PL-09 - Impact of preclinical variables on thrombotic biomarkers levels in cancer
R. Selby (Canada)

PL-10 - Biomarkers in cancer VTE: Data from the AVERT study patients
N. Key (USA)

PL-11 - Thrombotic biomarkers in occult cancer and cancer risk prediction
M. Marchetti (Italy) 

PL-12 - Genes and proteins associated with CAT risk
H. Versteeg (The Netherlands) 

PL-13 - Role of NETs in cancer associated-thrombosis
S. Zeerleder (Switzerland) 

Selected Abstract

OC-08 - Biomarkers of venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis (HISPALIS- Study)
R. Otero Candelera, V. Sánchez López, E. Arellano Orden,  J. Oto Martinez, A. Solier-López, S. Marín Romero, L. Jara Palomares, T. Elias Hernández, M.I. Asencio Cruz, I. Blasco-Esquivias, M. Rodriguez de la Borbolla, J.M. Sánchez Díaz, F.J. Rodriguez Martorell, P. Medina Badenes (Spain)

OC-09 - Proteomic profiling in cancer-associated VTE
M. Panova-Noeva, A. Schulz, T. Köck, V. ten Cate, B. Wagner, S. Rapp, M. Lenz, A. Zink, M. Ghadessi, S. Konstantinides, H. ten Cate, S. Heitmeier, P. Wild (Germany, The Netherlands)